Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | KAT6A | Q92794 | 6/20 | 0.52 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2633029 | 0.83 | PTGS2 (0.64) | PTGS2PTGS1EGFRKEAP1NFE2L2 | |
| SCHEMBL2626898 | 0.82 | SCN9A (0.43) | PTGS2PTGS1KAT6AP4HTM | |
| SCHEMBL15747005 | 0.81 | PTGS2 (0.49) | PTGS2PTGS1KAT6AEGFRKEAP1 | |
| SCHEMBL2626901 | 0.81 | SCN2B (0.42) | PTGS2PTGS1KAT6AEGFR | |
| SCHEMBL10074415 | 0.80 | SCN9A (0.41) | PTGS2PTGS1KAT6A | |
| SCHEMBL2632994 | 0.79 | SCN9A (0.59) | — | |
| SCHEMBL20233363 | 0.72 | KAT6A (0.61) | KAT6AEGFRKEAP1NFE2L2FGFR1 | |
| SCHEMBL20465509 | 0.68 | KAT6A (1.00) | KAT6A | |
| SCHEMBL2689196 | 0.68 | ELOVL1 (0.41) | EGFRFGFR1KDR | |
| SCHEMBL5931288 | 0.67 | FLT1 (0.71) | PTGS2PTGS1KAT6AEGFRP4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558458-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER IP GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-9339032-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9339032-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20140135346-A1 | Novel Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2014-05-15 | — | — | US | disclosed |
| US-20140135346-A1 | Novel Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2014-05-15 | — | — | US | disclosed |
| US-8664229-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664229-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20120095023-A1 | Novel Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120095023-A1 | Novel Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2012-04-19 | — | — | US | disclosed |
| WO-2011128304-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AG (DE) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135346-A1 | Novel Heterocyclic Compounds as Pesticides | DDT, PTMS, AADAC | PTGS2 1106/4885PTGS1 2076/4885KAT6A 2893/4885 |
| US-20120095023-A1 | Novel Heterocyclic Compounds as Pesticides | DDT, PTMS, AADAC | PTGS2 1106/4885PTGS1 2076/4885KAT6A 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.